SI2475368T1 - N-(4-((3-(2-amino-4-pirimidinil)-2-piiridin il)oksi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin za uporabo pri zdravljenju raka rezistentnega na antimitotiäśno sredstvo - Google Patents
N-(4-((3-(2-amino-4-pirimidinil)-2-piiridin il)oksi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin za uporabo pri zdravljenju raka rezistentnega na antimitotiäśno sredstvoInfo
- Publication number
- SI2475368T1 SI2475368T1 SI201030865T SI201030865T SI2475368T1 SI 2475368 T1 SI2475368 T1 SI 2475368T1 SI 201030865 T SI201030865 T SI 201030865T SI 201030865 T SI201030865 T SI 201030865T SI 2475368 T1 SI2475368 T1 SI 2475368T1
- Authority
- SI
- Slovenia
- Prior art keywords
- phthalazinamine
- pyrimidinyl
- pyridin
- thienyl
- oxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24152709P | 2009-09-11 | 2009-09-11 | |
| PCT/US2010/048247 WO2011031842A1 (en) | 2009-09-11 | 2010-09-09 | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
| EP10755044.4A EP2475368B1 (en) | 2009-09-11 | 2010-09-09 | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2475368T1 true SI2475368T1 (sl) | 2015-03-31 |
Family
ID=43216900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201030865T SI2475368T1 (sl) | 2009-09-11 | 2010-09-09 | N-(4-((3-(2-amino-4-pirimidinil)-2-piiridin il)oksi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin za uporabo pri zdravljenju raka rezistentnega na antimitotiäśno sredstvo |
Country Status (34)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015518053A (ja) * | 2012-05-31 | 2015-06-25 | アムジエン・インコーポレーテツド | 癌の治療のためのａｍｇ９００の使用 |
| CN103664737A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| US9963701B2 (en) | 2013-09-30 | 2018-05-08 | Korea Institute Of Radiological & Medical Sciences | Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor |
| KR102305351B1 (ko) | 2013-11-11 | 2021-09-24 | 암젠 인크 | 암의 치료를 위한, mdm2 억제제 및 하나 이상의 추가적 약제학적 활성 제제를 포함하는 조합 요법 |
| JP6634016B2 (ja) * | 2013-12-03 | 2020-01-22 | アムジエン・インコーポレーテツド | Ｎ−（４−（（３−（２−アミノ−４−ピリミジニル）−２−ピリジニル）オキシ）フェニル）−４−（４−メチル−２−チエニル）−１−フタラジンアミンの薬学的に許容される塩の結晶形態及びその使用 |
| CN106068263A (zh) * | 2014-02-21 | 2016-11-02 | 弗洛斯特生物科技有限公司 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
| BR112018071023A2 (pt) * | 2016-04-15 | 2019-02-05 | Felicitex Therapeutics Inc | combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| MA51848A (fr) | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| NZ782284A (en) | 2019-05-21 | 2024-11-29 | Amgen Inc | Solid state forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2531142A1 (en) * | 2003-07-03 | 2005-01-13 | Cambridge University Technical Services Ltd | Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| US7560551B2 (en) * | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| UA93538C2 (en) * | 2006-01-23 | 2011-02-25 | Амген Инк. | Aurora kinase modulators and method of use |
| CA2637658C (en) * | 2006-01-23 | 2012-07-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| GB0609619D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Combination |
| GB0609621D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
-
2010
- 2010-09-09 PL PL10755044T patent/PL2475368T3/pl unknown
- 2010-09-09 CN CN2010800512813A patent/CN102869361A/zh active Pending
- 2010-09-09 NZ NZ598758A patent/NZ598758A/en not_active IP Right Cessation
- 2010-09-09 HR HRP20150104AT patent/HRP20150104T1/hr unknown
- 2010-09-09 WO PCT/US2010/048247 patent/WO2011031842A1/en not_active Ceased
- 2010-09-09 UA UAA201204585A patent/UA107675C2/ru unknown
- 2010-09-09 PE PE2012000323A patent/PE20120895A1/es not_active Application Discontinuation
- 2010-09-09 HU HUE10755044A patent/HUE024568T2/hu unknown
- 2010-09-09 ME MEP-2015-10A patent/ME02048B/me unknown
- 2010-09-09 PT PT107550444T patent/PT2475368E/pt unknown
- 2010-09-09 BR BR112012008325A patent/BR112012008325A2/pt not_active IP Right Cessation
- 2010-09-09 RS RS20150065A patent/RS53807B1/sr unknown
- 2010-09-09 KR KR1020127009226A patent/KR20120082896A/ko not_active Ceased
- 2010-09-09 AU AU2010292225A patent/AU2010292225C1/en active Active
- 2010-09-09 DK DK10755044T patent/DK2475368T3/en active
- 2010-09-09 EA EA201270383A patent/EA020526B1/ru not_active IP Right Cessation
- 2010-09-09 SG SG2012017422A patent/SG179102A1/en unknown
- 2010-09-09 US US12/878,539 patent/US20120028917A1/en not_active Abandoned
- 2010-09-09 PH PH1/2012/500504A patent/PH12012500504A1/en unknown
- 2010-09-09 ES ES10755044.4T patent/ES2528485T3/es active Active
- 2010-09-09 CA CA2773838A patent/CA2773838C/en active Active
- 2010-09-09 EP EP14186203.7A patent/EP2818170B1/en active Active
- 2010-09-09 JP JP2012528891A patent/JP5851403B2/ja active Active
- 2010-09-09 MX MX2012003041A patent/MX2012003041A/es active IP Right Grant
- 2010-09-09 EP EP10755044.4A patent/EP2475368B1/en active Active
- 2010-09-09 SI SI201030865T patent/SI2475368T1/sl unknown
- 2010-09-10 TW TW099130742A patent/TW201121956A/zh unknown
-
2012
- 2012-03-11 IL IL218569A patent/IL218569A0/en unknown
- 2012-03-12 CL CL2012000640A patent/CL2012000640A1/es unknown
- 2012-03-12 TN TNP2012000110A patent/TN2012000110A1/en unknown
- 2012-04-04 ZA ZA2012/02472A patent/ZA201202472B/en unknown
- 2012-04-04 MA MA34753A patent/MA33658B1/fr unknown
- 2012-04-10 CR CR20120171A patent/CR20120171A/es unknown
-
2013
- 2013-01-16 HK HK15106028.6A patent/HK1205457A1/en unknown
-
2015
- 2015-02-09 SM SM201500028T patent/SMT201500028B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2475368E (pt) | N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4- metil-2-tienil)-1-ftalazinamina para utilização no tratamento de cancro resistente aos agentes antimitóticos | |
| ZA201103759B (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| IL248204A0 (en) | Combined treatment of tumors expressing 38cd | |
| SI2343070T1 (sl) | Zdravljenje s pirfenidonom za bolnike z atipiäśno jetrno funkcijo | |
| ZA200807234B (en) | GSK-3 inhibitors for the treatment of osteoporosis | |
| ZA200906126B (en) | Use of IL-23 antigonists for treatment of infection | |
| ZA200900734B (en) | Combination treatment for metabolic disorders | |
| MX315904B (es) | Inhibidores de fosfoinosituro-3 cinasa. | |
| EP2134431A4 (en) | RECARACTERIZATION OF PARIS AT THE TABLE GAMES | |
| IL196517A0 (en) | Jak inhibitors for treatment of myeloproliferative disorders | |
| PL2954932T3 (pl) | Zastosowanie terapeutyczne diaminofenotiazyn | |
| EP2049139A4 (en) | TREATMENT OF TUMORS EXPRESSING RAS | |
| EP2205236A4 (en) | NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS | |
| IL194189A0 (en) | Combination treatment of metabolic disorders | |
| SI2632921T1 (sl) | Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj | |
| IL212353A0 (en) | Compositions and methods for treatment of kidney disorders | |
| ZA201003425B (en) | 5-cyano-thienopyridines for the treatment of tumors | |
| IL238394B (en) | Preparations containing a combination of factors for the treatment of cancer | |
| HUE055524T2 (hu) | A bcrabl génben 1457T>C mutációt tartalmazó, imatinibbel szemben ellenálló krónikus mielogén leukémia kezelése bozutinib vegyület alkalmazásával | |
| EP2213303A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT | |
| ZA201000225B (en) | Treatment of depression | |
| ZA200901452B (en) | Treatment of vertigo with acetyl-L-leucine | |
| SI2331098T1 (sl) | Postopki za dajanje iloperidona | |
| SI2129377T1 (sl) | Tekoäśa formulacija soli 4-(2-(4-metilfenilsulfanil)fenil)piperidina | |
| IL194066A0 (en) | Therapeutic composition for treatment of tinnitus |